Indication for biologics in a real-world cohort of dupilumab treated chronic rhinosinusitis with nasal polyps patients according to international recommendations: evidence from the European CRS Outcome Registry (CHRINOSOR)

Real-world management of CRSwNP with biologics does not strictly follow the indication criteria established by international recommendations but depends on management criteria established by local authorities. These vary significantly and are either more or less stringent from one country to another. Dupilumab effectiveness in CRSwNP, whether these criteria are met or not, suggests that a broader CRSwNP population may benefit from dupilumab.

Authors

Institutions

Publication Details

Journal
Rhinology Journal
Published
2025-01-09
DOI
https://doi.org/10.4193/rhin25.157
Primary Topic
Sinusitis and nasal conditions
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Indication for biologics in a real-world cohort of dupilumab treated chronic rhinosinusitis with nasal polyps patients according to international recommendations: evidence from the European CRS Outcome Registry (CHRINOSOR)

Sven Schneider, M Wagenmann, Laura Van Gerven, Anu Laulajainen‐Hongisto et al.
5 links
Rhinology Journal
Sinusitis and nasal conditions
article

Indication for biologics in a real-world cohort of dupilumab treated chronic rhinosinusitis with nasal polyps patients according to international recommendations: evidence from the European CRS Outcome Registry (CHRINOSOR)

Sven Schneider, M Wagenmann, Laura Van Gerven, Anu Laulajainen‐Hongisto, Andrea Ciofalo, Sven Seys, Peter W. Hellings, Marco de Vincentiis, Zuzana Diamant, Simonetta Masieri, Peter Valentin Tomazic, Clemens Holzmeister, Jens Kjeldsen, Claus Bachert, Isam Alobid, Godelieve Mariën, Sietze Reitsma, Carlo Cavaliere, Kathrin Scheckenbach, G. Mortuaire, Julia Eckl‐Dorna, Josje Otten, Alexandros Andrianakis, C Hopkins, Valérie Hox, Valerie Lund, A Tu, W J Fokkens, Giulia Bettio, Joost de Kinderen
article en

Abstract

Real-world management of CRSwNP with biologics does not strictly follow the indication criteria established by international recommendations but depends on management criteria established by local authorities. These vary significantly and are either more or less stringent from one country to another. Dupilumab effectiveness in CRSwNP, whether these criteria are met or not, suggests that a broader CRSwNP population may benefit from dupilumab.

Rhinology JournalVol. 0(0)
Cliniques Universitaires Saint-Luc (BE), University of Helsinki (FI), Sun Yat-sen University (CN), Guy's and St Thomas' NHS Foundation Trust (GB), Medical University of Graz (AT), Charles University (CZ), Universitair Ziekenhuis Leuven (BE), Helsinki University Hospital (FI), Odense University Hospital (DK), Vienna General Hospital (AT), Centre Hospitalier Universitaire de Lille (FR), University Hospital Münster (DE), Hospital Clínic de Barcelona (ES), The First Affiliated Hospital, Sun Yat-sen University (CN), Royal National Throat Nose and Ear Hospital (GB), Thomayer University Hospital (CZ), Hôpital Claude Huriez (FR), Consorci Institut D'Investigacions Biomediques August Pi I Sunyer (ES), Medical University of Vienna (AT), Sapienza University of Rome (IT), KU Leuven (BE)
Openalex Percentile: Top 68%
Sinusitis and nasal conditions
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.